Im, Jihaeng
Kawada-Watanabe, Erisa
Yamaguchi, Junichi
Arashi, Hiroyuki
Otsuki, Hisao
Matsui, Yuko
Sekiguchi, Haruki
Fujii, Shinya
Mori, Fumiaki
Ogawa, Hiroshi
Hagiwara, Nobuhisa
Article History
Received: 13 August 2020
Accepted: 12 March 2021
First Online: 5 April 2021
Competing interests
: The authors declare no competing interests.
: All members of the HIJ-PROPER study group received research support to perform clinical trials from the Japan Research Promotion Society for Cardiovascular Diseases, which is sponsored by Abbott Vascular Japan Co., Ltd., AstraZeneca K.K., Bayer Yakuhin Ltd., Boston Scientific Corporation, Bristol-Myers K.K., Daiichi Sankyo Co., Ltd., Kowa Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Pfizer Japan Inc., Sanofi K.K., and Takeda Pharmaceutical Co., Ltd. NH reports honoraria from Bristol-Myers K.K. and Nippon Boehringer Ingelheim Co., Ltd., and grants from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Takeda Pharmaceutical Co., Ltd. JY and HO belong to the Clinical Research Division for Cardiovascular Catheter Intervention, which is financially maintained by donation from Abbott Vascular, Boston Scientific, Medtronic, and Terumo. The HIJ-PROPER Steering Committee has full access to all data of the present study and final responsibility for the decision to submit for publication.